Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.78 |
| ▸ | KCNA3 | P22001 | 5/20 | 0.71 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | BACE1 | P56817 | 2/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.64 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.64 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.62 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.62 |
| ▸ | ACHE | P22303 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.62 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7518456 | 0.88 | MAOA (0.68) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL17373028 | 0.88 | MAOA (1.00) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL6709622 | 0.86 | MAOA (0.78) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL3446041 | 0.86 | MAOA (0.78) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL18788617 | 0.86 | MAOA (0.78) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL14677742 | 0.86 | MAOA (0.73) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL31546585 | 0.86 | MAOA (0.77) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL9184365 | 0.85 | MAOA (0.76) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL6751059 | 0.84 | MAOA (0.74) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 | |
| SCHEMBL18788613 | 0.84 | MAOA (0.74) | MAOAKCNA3KCNA5CYP3A4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2018-06-21 | — | — | US | disclosed |
| US-20170113061-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | IMMUNOLIGHT, LLC (US) | 2017-04-27 | — | — | US | disclosed |
| US-4835263-A | Novel compounds containing an oligonucleotide sequence bonded to an intercalating agent, a process for their synthesis and their use | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 1989-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170113061-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | NFATC1, CDK10, CDK20 | MAOA 1698/4885KCNA3 4765/4885KCNA5 4037/4885 |
| US-20180169433-A1 | METHODS AND SYSTEMS FOR TREATING CELL PROLIFERATION DISORDERS WITH PSORALEN DERIVATIVES | NFATC1, CDK10, PDCD10 | MAOA 1133/4885KCNA3 4811/4885KCNA5 4175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.